Farcast Biosciences operates in the biotechnology sector, specializing in cancer drug discovery and immuno-oncology. The company serves pharmaceutical companies, biotech firms, and research institutions by providing a unique and proprietary histoculture platform. This platform uses fresh human tumor samples to evaluate therapeutic responses across various drug categories, including bi-specific antibodies, monoclonal antibodies, small molecules, and oncolytic viruses. Farcast Biosciences' technology maintains tumor morphology and viability, retaining native tumor architecture and immune components, thus enabling effective study of tumor response to drug treatments. The company offers a wide array of kinetic and end-point assays for multi-dimensional analysis of mechanistic action and impact of therapeutic agents on the tumor microenvironment. By partnering with IRB-approved cancer centers, Farcast Biosciences ensures access to fresh tumor samples from informed and consented patients, facilitating the study of inter-patient heterogeneity. The business model revolves around providing these specialized services to its clients, generating revenue through service fees and collaborative research agreements.

Keywords: histoculture platform, cancer drug discovery, immuno-oncology, fresh tumor samples, bi-specific antibodies, monoclonal antibodies, small molecules, oncolytic viruses, tumor microenvironment, kinetic assays.